Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2000

View Archived Issues

Phase III efficacy results reported for nalmefene in stroke

NIH awards phase I SBIR grant to Avanir for combination herpes therapy

InterMune Pharmaceuticals commences Actimmune trial in MDR-TB

Scotia licenses rights to Techniclone's VTA technology for use in PDT

SciClone begins marketing and distribution of Zadaxin in Mexico

Beta LT meets safety goals early in clinical trials

Initial trials demonstrate promise of PRO-542 HIV inhibitor

Tourette Syndrome symptoms improve with mecamylamine therapy

Human adenovirus linked to obesity in animals

First use of gene transfer to treat human neurodegenerative disease reported

Ampligen to be considered for orphan drug status in the E.U.

Licensing opportunity from NIH: leukocyte-based inhibition of viral replication

Oxcarbazepine shown to be beneficial in treating refractory partial epilepsy

FDA approves Rescula for treatment of glaucoma

Reminyl receives FDA approvable letter

Pfizer discontinues phase III trials of prinomastat in advanced cancers

PTSD indication sought for Paxil in Canada

Cell Pathways completes phase Ib trial of CP-461

New compounds under development at AstraZeneca for treatment of thrombosis

New compounds interacting with chemokine receptors under study at DuPont

New series of cyclic pyrazine derivatives useful for diabetes

New benzene derivatives useful for pulmonary thrombosis

New TNF inhibitors under development at Daiichi

Novel compounds under study at Melacure Therapeutics for treatment of eating disorders

New PDE5 inhibitors under study at Fujisawa useful for diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...